A study has confirmed that 20–30% of patients with breast cancer have a high expression of HER-2 and that overexpression of HER-2 in patients correlates with a poor prognosis and resistance to cytotoxic chemotherapeutic drugs (13). Here, ERBB2 is linked to breast cancer.